跳至主要内容
临床试验/CTRI/2020/06/025819
CTRI/2020/06/025819尚未招募4 期

A Prospective Multi-centre, Noninterventional,observational Post Marketing Surveillance (PMS) Study of RituxiRelTM RN(Rituximab) to Evaluate long-term safety in Patients with Pemphigus Vulgaris in Routine Clinical Practice

Reliance Life Sciences Pv Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • The patient inclusion will be sole decision of the Dermatologists according to his routine
  • practice. Minimum inclusion criteria clinically required can be as follows which will be at solediscretion of the Dermatologists.
  • Adults (18 through 70 years of age) with clinically-documented diagnosis of moderate to
  • severe Pemphigus vulgaris

排除标准

  • Pregnant women, nursing mothers or a planned pregnancy within 18 months,Allergy to rituximab and any of the excipients of RituxiRelTM RN (rituximab), Active TB. Also excluded are patients who have evidence of latent TB [evidence of tuberculosisbased on chest X rays, QuantiFERON®-TB Gold test and other TB tests performed during screening]. Also excluded are patients with opportunistic infections including, but not limited to,evidence of active cytomegalovirus, active pneumocystis carinii, aspergillosis, or typical mycobacterial infection, etc., within the previous 6 months

研究者

发起方
Reliance Life Sciences Pv Ltd

相似试验